secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0000950170-23-048186
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences Q1 FY2024: no revenue, $576K cash; MyoVista FDA submission targeted for late 2023
--------------------------------------------------------------------------------

- No revenue for Q1 FY2024; cash and equivalents of $576K as of July 31, 2023.
- Completed enrollment for MyoVista pivotal study; targeting FDA submission in late 2023.
- Expanded IP portfolio to 41 patents (9 US, 32 international); appointed new distributors in Nordic and India.
- Secured $15M equity line (March 2023) and $1M promissory note (Sept 2023) for funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023048186/0000950170-23-048186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000095017023048186/hscs-20230914.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-048186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer